Title:ISATIN: New Hope Against Convulsion
VOLUME: 18 ISSUE: 2
Author(s):Rameshwar S. Cheke, Sandip D. Firke*, Ravindra R. Patil and Sanjay B. Bari
Affiliation:Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, 425405 Maharashtra, Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, 425405 Maharashtra, Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, 425405 Maharashtra, Department of Pharmaceutical Chemistry, H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, 425405 Maharashtra
Keywords:Anticonvulsant, docking, isatin, MES, sc-PTZ, epilepsy.
Abstract:Background: Epilepsy is one in every of the foremost important chronic neurological disorders
with high incidence worldwide. Several epileptic patients don’t seem to be fully treated with
currently available marketed medicines likewise so many drugs have shown unfavorable side effect
and drug interaction. Therefore, there are continuing interests to seek out new anticonvulsant drugs.
Methods: Literature search was carried out to indentify isatin containing derivatives as anticonvulsant
drugs.
Results: Common synthetic schemes were studied to design and develop isatin derives anticonvulsant
agents. Various structural features essential for the design of isatin compounds were reported. Anticonvulsant
activity is evaluated by different tests were identified and their results can be considered
for the design of novel isatin derivatives as anticonvulsants.
Conclusion: In outline, isatin has been proved to be an excellent hybrid building the molecule with
interesting biological activities. Among the prospect of derivatizing the N1, C2 and C3 positions,
along with substitution on the aromatic ring, the synthetic modification for isatin is almost endless.
Despite the fact that isatin derivatives are well-studied compounds, new derivatives are continually being
discovered on the basis of known AEDs, isatin has been fused with other bioactive drug fragments
and subsequently investigated as hybrid/dual action drugs and selectively targeted against convulsion.
